<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EFFIENTÂ - prasugrel hydrochlorideÂ tablet, film coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Effient safely and effectively. See full prescribing information for Effient.
	<br>
	EFFIENTÂ (prasugrel) tablets
	<br>
	Initial U.S. Approval: 2009</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> RISK</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete <a href="#s1"> boxed warning</a></span></h1>
<p class="Highlighta"><span class="Bold">Effient can cause significant, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#s11">5.1</a>, <a href="#s12">5.2</a>, and <a href="#s16">6.1</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Do not use Effient in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or a history of transient ischemic attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (<a href="#s8">4.1</a> and <a href="#s9">4.2</a>).</span> </p>
<p class="Highlighta"><span class="Bold">In patients â‰¥ 75 years of age, Effient is generally not recommended because of the increased risk of fatal and intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and uncertain benefit, except in high-risk patients (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or prior MI), where its effect appears to be greater and its use may be considered (<a href="#s33">8.5</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.</span> </p>
<p class="Highlighta"><span class="Bold">Additional risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> include:</span> </p>
<ul class="Disc">
<li><span class="Bold">body weight &lt; 60 kg</span></li>
<li><span class="Bold">propensity to bleed</span></li>
<li><span class="Bold">concomitant use of medications that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Suspect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.</span> </p>
<p class="Highlighta"><span class="Bold">If possible, manage <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> without discontinuing Effient. Stopping Effient, particularly in the first few weeks after <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, increases the risk of subsequent cardiovascular events (<a href="#s13">5.3</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Contraindications, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s9b">4.3</a>)Â Â Â Â Â Â Â Â Â 12/2010 </p>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span> (<a href="#s14">5.4</a>)Â Â Â Â Â Â Â Â Â 12/2010 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> RISK</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete <a href="#s1"> boxed warning</a></span></h1>
<p class="Highlighta"><span class="Bold">Effient can cause significant, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#s11">5.1</a>, <a href="#s12">5.2</a>, and <a href="#s16">6.1</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Do not use Effient in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or a history of transient ischemic attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (<a href="#s8">4.1</a> and <a href="#s9">4.2</a>).</span> </p>
<p class="Highlighta"><span class="Bold">In patients â‰¥ 75 years of age, Effient is generally not recommended because of the increased risk of fatal and intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and uncertain benefit, except in high-risk patients (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or prior MI), where its effect appears to be greater and its use may be considered (<a href="#s33">8.5</a>).</span> </p>
<p class="Highlighta"><span class="Bold">Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.</span> </p>
<p class="Highlighta"><span class="Bold">Additional risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> include:</span> </p>
<ul class="Disc">
<li><span class="Bold">body weight &lt; 60 kg</span></li>
<li><span class="Bold">propensity to bleed</span></li>
<li><span class="Bold">concomitant use of medications that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Suspect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.</span> </p>
<p class="Highlighta"><span class="Bold">If possible, manage <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> without discontinuing Effient. Stopping Effient, particularly in the first few weeks after <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, increases the risk of subsequent cardiovascular events (<a href="#s13">5.3</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Effient is a P2Y<span class="Sub">12</span> platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>) in patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> who are to be managed with PCI as follows: </p>
<ul class="Disc">
<li>
							Patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or, non-ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (NSTEMI) (<a href="#s3">1.1</a>).
						</li>
<li>
							Patients with ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) when managed with either primary or delayed PCI (<a href="#s3">1.1</a>).
						</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
							Initiate treatment with a single 60 mg oral loading dose (<a href="#s4">2</a>).
						</li>
<li>
							Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients &lt;60 kg (<a href="#s4">2</a>).
						</li>
<li>
							Patients should also take aspirin (75Â mg to 325Â mg) daily (<a href="#s4">2</a>).
						</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">5Â mg and 10Â mg tablets (<a href="#s6">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>
							Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#s8">4.1</a>)
						</li>
<li>
							Prior transient ischemic attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (<a href="#s9">4.2</a>)
						</li>
<li>
							<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to prasugrel or any component of the product (<a href="#s9b">4.3</a>)
						</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
							CABG-related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: Risk increases in patients receiving Effient who undergo CABG (<a href="#s12">5.2</a>).
						</li>
<li>
							Discontinuation of Effient: Premature discontinuation increases risk of stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, MI, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#s13">5.3</a>).
						</li>
<li>
							<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> (TTP): TTP has been reported with Effient  (<a href="#s14">5.4</a>).
						</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, including life-threatening and fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, is the most commonly reported adverse reaction (<a href="#s16">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> RISK</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Prior Transient Ischemic Attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Coronary Artery Bypass Graft Surgery-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Discontinuation of Effient</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Warfarin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Non-Steroidal Anti-Inflammatory Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other Concomitant Medications</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Low Body Weight</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.9 Metabolic Status</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and Symptoms</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Recommendations about Specific Treatment</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Benefits and Risks</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Other Signs and Symptoms Requiring Medical Attention</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Invasive Procedures</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Concomitant Medications</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> RISK</h1>
<p class="First"><span class="Bold">Effient can cause significant, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </span><span class="Bold Italics">[see Warnings and Precautions (<a href="#s11">5.1</a> and <a href="#s12">5.2</a>) and Adverse Reactions (<a href="#s16">6.1</a>)]</span>.</p>
<p><span class="Bold">Do not use Effient in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or a history of transient ischemic attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></span><span class="Bold Italics"> [see Contraindications (<a href="#s8">4.1</a> and <a href="#s9">4.2</a>)]</span>.</p>
<p><span class="Bold">In patients â‰¥ 75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and uncertain benefit, except in high-risk situations (patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a history of prior MI) where its effect appears to be greater and its use may be considered</span><span class="Bold Italics"> [see Use in Specific Populations (<a href="#s33">8.5</a>)]</span>.</p>
<p><span class="Bold">Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.</span></p>
<p><span class="Bold">Additional risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> include:</span></p>
<ul class="Disc">
<li><span class="Bold">body weight &lt; 60 kg</span></li>
<li><span class="Bold">propensity to bleed</span></li>
<li>
<span class="Bold">concomitant use of medications that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (</span><span class="Bold Italics">e.g.</span><span class="Bold">, warfarin, heparin, fibrinolytic therapy, chronic use of non-steroidal anti-inflammatory drugs [NSAIDS])</span>
</li>
</ul>
<p><span class="Bold">Suspect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.</span></p>
<p><span class="Bold">If possible, manage <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, increases the risk of subsequent cardiovascular events</span><span class="Bold Italics"> [see Warnings and Precautions (<a href="#s13">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span></h2>
<p class="First">Effientâ„¢ is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>) in patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:</p>
<ul class="Disc">
<li>
							Patients with unstable anginaÂ (UA) or non-ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (NSTEMI).
						</li>
<li>
							Patients with ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) when managed with primary or delayed PCI.
						</li>
</ul>
<p>Effient has been shown to reduce the rate of a combined endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI), or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and little difference on CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see Clinical Studies (<a href="#s75">14</a>)]</span>.</p>
<p>It is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to UA/NSTEMI patients until coronary anatomy was established. For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was substantial <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.2</a>)]</span>. Because the large majority of patients are managed without CABG, however, treatment can be considered before determining coronary anatomy if need for CABG is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients who do need to undergo urgent CABG.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Initiate Effient treatment as a single 60 mg oral loading dose and then continue at 10Â mg orally once daily. Patients taking Effient should also take aspirinÂ (75Â mg to 325Â mg) daily <span class="Italics">[see Drug Interactions (<a href="#s24">7</a>) and Clinical Pharmacology (<a href="#s45">12.3</a>)]</span>. Effient may be administered with or without food <span class="Italics">[see Clinical PharmacologyÂ (<a href="#s45">12.3</a>) and Clinical StudiesÂ (<a href="#s75">14</a>)]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Underline">Dosing in <span class="product-label-link" type="condition" conceptid="435372" conceptname="Underweight">Low Weight</span> Patients</span></p>
<p>Compared to patients weighing â‰¥ 60 kg, patients weighing &lt; 60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on a 10 mg once daily maintenance dose. Consider lowering the maintenance dose to 5 mg in patients &lt; 60 kg. The effectiveness and safety of the 5 mg dose have not been prospectively studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">EffientÂ 5 mg is a yellow, elongated hexagonal, film-coated, non-scored tablet debossed with â€œ5Â MGâ€? on one side and â€œ4760â€? on the other side.</p>
<p>EffientÂ 10 mg is a beige, elongated hexagonal, film-coated, non-scored tablet debossed with â€œ10Â MGâ€? on one side and with â€œ4759â€? on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Effient is contraindicated in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> such as <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.1</a>) and Adverse ReactionsÂ (<a href="#s16">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Prior Transient Ischemic Attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></h2>
<p class="First">Effient is contraindicated in patients with a history of prior transient ischemic attack (TIA) or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. In TRITON-TIMI 38 (<span class="Underline">TR</span>ial to Assess <span class="Underline">I</span>mprovement in <span class="Underline">T</span>herapeutic Outcomes by <span class="Underline">O</span>ptimizing Platelet Inhibitio<span class="Underline">N</span> with Prasugrel), patients with a history of TIA or <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (&gt; 3 months prior to enrollment) had a higher rate of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> on Effient (6.5%; of which 4.2% were <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic stroke</span> and 2.3% were <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Effient and clopidogrel, respectively. Patients with a history of <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> within 3 months of screening and patients with a history of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> at any time were excluded from TRITON-TIMI 38. Patients who experience a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA while on Effient generally should have therapy discontinued <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>) and Clinical Studies (<a href="#s75">14</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9b"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Effient is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to prasugrel or any component of the product <span class="Italics">[see Adverse Reactions (<a href="#s16b">6.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s10"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.1"></a><p></p>
<h2>5.1 General Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Thienopyridines, including Effient, increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. With the dosing regimens used in TRITON-TIMI 38, TIMI (<span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">Thrombolysis</span> in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>) Major (clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hemoglobin â‰¥ 5Â g/dL, or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>) and TIMI Minor (overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hemoglobin of â‰¥ 3Â g/dL but &lt; 5Â g/dL) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events were more common on Effient than on clopidogrel <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span>. The <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk is highest initially, as shown in <a href="#f01">Figure 1</a> (events through 450 days; inset shows events through 7 days).</p>
<div class="Figure">
<a name="f01"></a><img alt="
							Figure 1
						" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-07.jpg"><p class="MultiMediaCaption">FigureÂ 1: Non-CABG-Related TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events</p>
</div>
<p>Suspect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in any patient who is hypotensive and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures even if the patient does not have overt signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Do not use Effient in patients with active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, prior TIA or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see Contraindications (<a href="#s8">4.1</a> and <a href="#s9">4.2</a>)]</span>.</p>
<p>Other risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are:</p>
<ul class="Disc">
<li>
							Age â‰¥ 75Â years. Because of the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (including fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) and uncertain effectiveness in patients â‰¥ 75 years of age, use of Effient is generally not recommended in these patients, except in high-risk situations (patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) where its effect appears to be greater and its use may be considered <span class="Italics">[see Adverse ReactionsÂ (<a href="#s16">6.1</a>), Use in Specific PopulationsÂ (<a href="#s33">8.5</a>), Clinical PharmacologyÂ (<a href="#s45">12.3</a>), and Clinical Trials (<a href="#s75">14</a>)]</span>.
						</li>
<li>
							CABG or other surgical procedure <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.2</a>)]</span>.
						</li>
<li>
							Body weight &lt; 60Â kg. Consider a lower (5 mg) maintenance dose <span class="Italics">[see Dosage and Administration (<a href="#s4">2</a>), Adverse ReactionsÂ (<a href="#s16">6.1</a>), Use in Specific PopulationsÂ (<a href="#s34">8.6</a>)]</span>.
						</li>
<li>
							Propensity to bleed (e.g., recent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, recent surgery, recent or recurrent gastrointestinal (GI) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>) <span class="Italics">[see Adverse ReactionsÂ (<a href="#s16">6.1</a>) and Use in Specific PopulationsÂ (<a href="#s36">8.8</a>)]</span>.
						</li>
<li>
							Medications that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<span class="Italics">e.g.</span>, oral anticoagulants, chronic use of non-steroidal anti-inflammatory drugs [NSAIDs], and fibrinolytic agents). Aspirin and heparin were commonly used in TRITON-TIMI 38 <span class="Italics">[see Drug InteractionsÂ (<a href="#s24">7</a>), Clinical Studies (<a href="#s75">14</a>)]</span>.
						</li>
</ul>
<p>Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7-10 days), so withholding a dose will not be useful in managing a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event or the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with an invasive procedure. Because the half-life of prasugrel's active metabolite is short relative to the lifetime of the platelet, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 6 hours of the loading dose or 4 hours of the maintenance dose may be less effective.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Coronary Artery Bypass Graft Surgery-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">The risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is increased in patients receiving Effient who undergo CABG. If possible, Effient should be discontinued at least 7 days prior to CABG.</p>
<p>Of the 437 patients who underwent CABG during TRITON-TIMI 38, the rates of CABG-related TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were 14.1% in the Effient group and 4.5% in the clopidogrel group <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span>. The higher risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in patients treated with Effient persisted up to 7 days from the most recent dose of study drug. For patients receiving a thienopyridine within 3 days prior to CABG, the frequencies of TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were 26.7% (12 of 45 patients) in the Effient group, compared with 5.0% (3 of 60 patients) in the clopidogrel group. For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group.</p>
<p>Do not start Effient in patients likely to undergo urgent CABG. CABG-related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be treated with transfusion of blood products, including packed red blood cells and platelets; however, platelet transfusions within 6 hours of the loading dose or 4 hours of the maintenance dose may be less effective.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Discontinuation of Effient</h2>
<p class="First">Discontinue thienopyridines, including Effient, for active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, elective surgery, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or TIA. The optimal duration of thienopyridine therapy is unknown. In patients who are managed with PCI and stent placement, premature discontinuation of any antiplatelet medication, including thienopyridines, conveys an increased risk of stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients who require premature discontinuation of a thienopyridine will be at increased risk for cardiac events. Lapses in therapy should be avoided, and if thienopyridines must be temporarily discontinued because of an adverse event(s), they should be restarted as soon as possible <span class="Italics">[see Contraindications (<a href="#s8">4.1</a> and <a href="#s9">4.2</a>) and Warnings and Precautions (<a href="#s11">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> (TTP) has been reported with the use of Effient.  TTP can occur after a brief exposure (&lt; 2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment, including plasmapheresis (plasma exchange). TTP is characterized by <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span> (schistocytes [fragment red blood cells] seen on peripheral smear), neurological findings, renal dysfunction, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <span class="Italics">[see Adverse Reactions (<a href="#s16b">6.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">The following serious adverse reactions are also discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li>
								<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#s1">Boxed Warning</a> and Warnings and Precautions (<a href="#s11">5.1</a>, <a href="#s12">5.2</a>)]</span>
</li>
<li>
									<span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> <span class="Italics">[see Warnings and Precautions (<a href="#s14">5.4</a>)]</span>
</li>
</ul>
<p>Safety in patients with ACS undergoing PCI was evaluated in a clopidogrel-controlled study, TRITON-TIMI 38, in which 6741Â patients were treated with Effient (60 mg loading dose and 10Â mg once daily) for a median of 14.5Â months (5802Â patients were treated for over 6Â months; 4136Â patients were treated for more than 1Â year). The population treated with Effient was 27 to 96Â years of age, 25%Â female, and 92%Â Caucasian. All patients in the TRITON-TIMI 38 study were to receive aspirin. The dose of clopidogrel in this study was a 300 mg loading dose and 75Â mg once daily.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared with the rates observed in other clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Drug Discontinuation</span></p>
<p>The rate of study drug discontinuation because of adverse reactions was 7.2% for Effient and 6.3% for clopidogrel. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> was the most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for Effient and 1.4% for clopidogrel).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Unrelated to CABG Surgery</span> - In TRITON-TIMI 38, overall rates of TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse reactions unrelated to coronary artery bypass graft surgery (CABG) were significantly higher on Effient than on clopidogrel, as shown in <a href="#t300">TableÂ 1</a>.</p>
<a name="t300"></a><table width="100%">
<caption><span>TableÂ 1: Non-CABG-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><span class="Sup">a</span> (TRITON-TIMI 38)</span></caption>
<col align="left" width="43.211%">
<col align="left" width="22.081%">
<col align="left" width="20.380%">
<col align="left" width="14.329%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Effient</span><br><span class="Bold">(%)</span><br><span class="Bold">(N=6741)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Clopidogrel</span><br><span class="Bold">(%)</span><br><span class="Bold">(N=6716)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">p-value</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">a</span> Patients may be counted in more than one row.</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Sup">b</span> See <a href="#s11">5.1</a> for definition.</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													4.5
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													3.4
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													p=0.002
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													TIMI Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
														2.2
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														1.7
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														p=0.029
													</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â Life-threatening
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														1.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.8
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														p=0.015
													</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â  Â Â Â Â Fatal
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.1
													</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â  Â Â Â Â Symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> (ICH)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â  Â Â Â Â Requiring inotropes
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.1
													</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â  Â Â Â Â Requiring <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														Â Â Â Â  Â Â Â Â Requiring transfusionÂ (â‰¥4Â units)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.7
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.5
													</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
														TIMI Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
															2.4
														</td>
<td class="Botrule Rrule" align="center" valign="top">
															1.9
														</td>
<td class="Botrule Rrule" align="center" valign="top">
															p=0.022
														</td>
</tr>
</tbody>
</table>
<p><a href="#f01">Figure 1</a> demonstrates non-CABG related TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate is highest initially, as shown in <a href="#f01">Figure 1</a> (inset: Days 0 to 7) <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.1</a>)]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> rates in patients with the risk factors of age â‰¥ 75 years and weight &lt; 60 kg are shown in <a href="#t2">Table 2</a>.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rates for Non-CABG-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> by Weight and Age (TRITON-TIMI 38)</span></caption>
<col align="left" width="39.788%">
<col align="left" width="15.323%">
<col align="left" width="15.323%">
<col align="left" width="15.323%">
<col align="left" width="14.243%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Major/Minor</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Fatal</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Effient</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Clopidogrel</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Effient</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Clopidogrel</span><br><span class="Bold">(%)</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">
														Weight &lt; 60 kg (N=308 Effient, N=356 clopidogrel)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														10.1
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														6.5
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.0
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
														Weight â‰¥ 60 kg (N=6373 Effient, N=6299 clopidogrel)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														4.2
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														3.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.3
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.1
													</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
														Age &lt; 75 years (N=5850 Effient, N=5822 clopidogrel)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														3.8
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														2.9
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.2
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.1
													</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
														Age â‰¥ 75 years (N=891 Effient, N=894 clopidogrel)
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														9.0
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														6.9
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														1.0
													</td>
<td class="Botrule Rrule" align="center" valign="top">
														0.1
													</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Related to CABG</span> - In TRITON-TIMI 38, 437Â patients who received a thienopyridine underwent CABG during the course of the study. The rate of CABG-related TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was 14.1% for the Effient group and 4.5% in the clopidogrel group (<a href="#t301">Table 3</a>). The higher risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse reactions in patients treated with Effient persisted up to 7Â days from the most recent dose of study drug.</p>
<a name="t301"></a><table width="100%">
<caption><span>TableÂ 3: CABG-Related <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><span class="Sup">a</span> (TRITON-TIMI 38)</span></caption>
<col align="left" width="39.800%">
<col align="left" width="28.900%">
<col align="left" width="31.300%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Effient (%)</span><br><span class="Bold">(N=213)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Clopidogrel (%)</span><br><span class="Bold">(N=224)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Patients may be counted in more than one row.</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													TIMI Major or Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													14.1
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													4.5
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													TIMI Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													11.3
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													3.6
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													Â Â Â Â Fatal
												</td>
<td class="Botrule Rrule" align="center" valign="bottom">
													0.9
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													0
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													Â Â Â Â Reoperation
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													3.8
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													0.5
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													Â Â Â Â Transfusion of â‰¥5 units
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													6.6
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													2.2
												</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													Â Â Â Â <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span>
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													0
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													0
												</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">
													TIMI Minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													2.8
												</td>
<td class="Botrule Rrule" align="center" valign="top">
													0.9
												</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Reported as Adverse Reactions</span> - Hemorrhagic events reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively: <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (6.2%, 3.3%), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (1.5%, 1.0%), <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> (0.6%, 0.5%), <span class="product-label-link" type="condition" conceptid="436204" conceptname="Subcutaneous hematoma">subcutaneous hematoma</span> (0.5%, 0.2%), post-procedural <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (0.5%, 0.2%), <span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">retroperitoneal hemorrhage</span> (0.3%, 0.2%), <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>/tamponade (0.3%, 0.2%), and <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span> (0.0%, 0.1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Underline">Malignancies</span></p>
<p>During TRITON-TIMI 38, newly diagnosed malignancies were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively. The sites contributing to the differences were primarily colon and lung. It is unclear if these observations are causally-related or are random occurrences.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Underline">Other Adverse Events</span></p>
<p>In TRITON-TIMIÂ 38, common and other important non-hemorrhagic adverse events were, for Effient and clopidogrel, respectively: severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (0.06%, 0.04%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (2.2%, 2.0%), abnormal hepatic function (0.22%, 0.27%), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (0.36%, 0.36%), and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (0.06%, 0.04%). <a href="#t4">Table 4</a> summarizes the adverse events reported by at least 2.5% of patients.</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Non-Hemorrhagic Treatment Emergent Adverse Events Reported by at Least 2.5% of Patients in Either Group</span></caption>
<col align="left" width="46.600%">
<col align="left" width="27.200%">
<col align="left" width="26.200%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
												Effient (%)
												<br>
												(N=6741)
											</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
												Clopidogrel (%)
												<br>
												(N=6716)
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												7.5
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												7.1
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span>/<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												7.0
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												7.4
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												5.5
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												5.3
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												5.0
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.5
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.9
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.5
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.6
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.3
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.1
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.6
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.9
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.1
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.9
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.8
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.7
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												4.8
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="4164649" conceptname="Non-cardiac chest pain">Non-cardiac chest pain</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.1
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.5
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.9
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.1
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.9
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.4
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (&lt; 4 x 10<span class="Sup">9</span> WBC/L)
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.8
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.5
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.8
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.4
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.7
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.2
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.7
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												3.0
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.6
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.6
											</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
												<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.3
											</td>
<td class="Botrule Rrule" align="center" valign="top">
												2.6
											</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of Effient.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17b"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Blood and lymphatic system disorders -</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span> (TTP) <span class="Italics">[see Warnings and Precautions (<a href="#s14">5.4</a>) and Patient Counseling Information (<a href="#s80">17.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18b"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span> -</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> <span class="Italics">[see Contraindications (<a href="#s9b">4.3</a>)]</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s24"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Warfarin</h2>
<p class="First">Coadministration of Effient and warfarin increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.1</a>) and Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Non-Steroidal Anti-Inflammatory Drugs</h2>
<p class="First">Coadministration of Effient and NSAIDs (used chronically) may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other Concomitant Medications</h2>
<p class="First">Effient can be administered with drugs that are inducers or inhibitors of cytochromeÂ P450 enzymes <span class="Italics">[see Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
<p>Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H<span class="Sub">2</span> blockers <span class="Italics">[see Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s28"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s29"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy CategoryÂ B</span> - There are no adequate and well-controlled studies of Effient use in pregnant women. Reproductive and developmental toxicology studies in rats and rabbits at doses of up to 30 times the recommended therapeutic exposures in humans (based on plasma exposures to the major circulating human metabolite) revealed no evidence of fetal harm; however, animal studies are not always predictive of a human response. Effient should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.</p>
<p>In embryo fetal developmental toxicology studies, pregnant rats and rabbits received prasugrel at maternally toxic oral doses equivalent to more than 40 times the human exposure. A slight decrease in pup body weight was observed; but, there were no structural malformations in either species. In prenatal and postnatal rat studies, maternal treatment with prasugrel had no effect on the behavioral or reproductive development of the offspring at doses greater than 150 times the human exposure <span class="Italics">[see Nonclinical Toxicology (<a href="#s71">13.1</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s31"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Effient is excreted in human milk; however, metabolites of Effient were found in rat milk. Because many drugs are excreted in human milk, prasugrel should be used during nursing only if the potential benefit to the mother justifies the potential risk to the nursing infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s32"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established <span class="Italics">[see Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s33"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In TRITON-TIMI 38, 38.5% of patients were â‰¥65Â years of age and 13.2% were â‰¥75Â years of age. The risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increased with advancing age in both treatment groups, although the relative risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (Effient compared with clopidogrel) was similar across age groups.</p>
<p>Patients â‰¥ 75Â years of age who received Effient had an increased risk of fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events (1.0%) compared to patients who received clopidogrel (0.1%). In patients â‰¥ 75 years of age, symptomatic <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> occurred in 7 patients (0.8%) who received Effient and in 3 patients (0.3%) who received clopidogrel. Because of the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and because effectiveness is uncertain in patients â‰¥ 75 years of age <span class="Italics">[see Clinical Studies (<a href="#s75">14</a>)]</span>, use of Effient is generally not recommended in these patients, except in high-risk situations (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and past history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) where its effect appears to be greater and its use may be considered <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.1</a>), Clinical Pharmacology (<a href="#s45">12.3</a>), and Clinical Studies (<a href="#s75">14</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Low Body Weight</h2>
<p class="First">In TRITON-TIMI 38, 4.6% of patients treated with Effient had body weight &lt;60Â kg. Individuals with body weight &lt; 60Â kg had an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and an increased exposure to the active metabolite of prasugrel <span class="Italics">[see Dosage and AdministrationÂ (<a href="#s4">2</a>), Warnings and PrecautionsÂ (<a href="#s11">5.1</a>), and Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>. Consider lowering the maintenance dose to 5 mg in patients &lt;60 kg. The effectiveness and safety of the 5 mg dose have not been prospectively studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There is limited experience in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> <span class="Italics">[see Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild to moderate hepatic impairmentÂ (Child-Pugh Class A and B). The pharmacokinetics and pharmacodynamics of prasugrel in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> have not been studied, but such patients are generally at higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and PrecautionsÂ (<a href="#s11">5.1</a>) and Clinical PharmacologyÂ (<a href="#s45">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-8.8"></a><p></p>
<h2>8.9 Metabolic Status</h2>
<p class="First">In healthy subjects, patients with stable <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s38"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and Symptoms</h2>
<p class="First">Platelet inhibition by prasugrel is rapid and irreversible, lasting for the life of the platelet, and is unlikely to be increased in the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In rats, lethality was observed after administration of 2000Â mg/kg. Symptoms of acute toxicity in dogs included <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, increased serum alkaline phosphatase, and hepatocellular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. Symptoms of acute toxicity in rats included <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, irregular respiration, decreased locomotor activity, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering gait</span>, and <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Recommendations about Specific Treatment</h2>
<p class="First">Platelet transfusion may restore clotting ability. The prasugrel active metabolite is not likely to be removed by dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s41"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Effient contains prasugrel, a thienopyridine class inhibitor of platelet activation and aggregation mediated by the P2Y<span class="Sub">12</span>Â ADP receptor. Effient is formulated as the hydrochloride salt, a racemate, which is chemically designated as 5-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride. Prasugrel hydrochloride has the empirical formula C<span class="Sub">20</span>H<span class="Sub">20</span>FNO<span class="Sub">3</span>Sâ€¢HCl representing a molecular weight of 409.90. The chemical structure of prasugrel hydrochloride is:</p>
<div class="Figure">
<a name="f11"></a><img alt="
						Chemical Structure
					" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-01.jpg">
</div>
<p>Prasugrel hydrochloride is a white to practically white solid. It is soluble at pHÂ 2, slightly soluble at pHÂ 3 to 4, and practically insoluble at pHÂ 6 to 7.5. It also dissolves freely in methanol and is slightly soluble in 1- and 2-propanol and acetone. It is practically insoluble in diethyl ether and ethyl acetate.</p>
<p>Effient is available for oral administration as 5Â mg or 10Â mg elongated hexagonal, film-coated, non-scored tablets, debossed on each side. Each yellow 5 mg tablet is manufactured with 5.49 mg prasugrel hydrochloride, equivalent to 5 mg prasugrel and each beige 10Â mg tablet with 10.98Â mg prasugrel hydrochloride, equivalent to 10Â mg of prasugrel. During manufacture and storage, partial conversion from prasugrel hydrochloride to prasugrel free base may occur. Other ingredients include mannitol, hypromellose, croscarmellose sodium, microcrystalline cellulose, and vegetable magnesium stearate. The color coatings contain lactose, hypromellose, titanium dioxide, triacetin, iron oxide yellow, and iron oxide red (only in Effient 10 mg tablet).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s42"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s43"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y<span class="Sub">12</span> class of ADPÂ receptors on platelets.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s44"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Prasugrel produces inhibition of platelet aggregation to 20Â Î¼M or 5Â Î¼M ADP, as measured by light transmission aggregometry. Following a 60-mg loading dose of Effient, approximately 90% of patients had at least 50% inhibition of platelet aggregation by 1Â hour. Maximum platelet inhibition was about 80% (<a href="#f02">Figure 2</a>). Mean steady-state inhibition of platelet aggregation was about 70% following 3Â to 5Â days of dosing at 10 mg daily after a 60-mg loading dose of Effient.</p>
<div class="Figure">
<a name="f02"></a><img alt="
									Figure 2
								" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-08.jpg"><p class="MultiMediaCaption">Figure 2: Inhibition (MeanÂ±SD) of 20Â Î¼M ADP-induced Platelet AggregationÂ (IPA) Measured by Light Transmission Aggregometry after Prasugrel 60Â mg</p>
</div>
<p>Platelet aggregation gradually returns to baseline values over 5-9 days after discontinuation of prasugrel, this time course being a reflection of new platelet production rather than pharmacokinetics of prasugrel. Discontinuing clopidogrel 75 mg and initiating prasugrel 10 mg with the next dose resulted in increased inhibition of platelet aggregation, but not greater than that typically produced by a 10 mg maintenance dose of prasugrel alone. The relationship between inhibition of platelet aggregation and clinical activity has not been established.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s45"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Prasugrel is a prodrug and is rapidly metabolized to a pharmacologically active metabolite and inactive metabolites. The active metabolite has an elimination half-life of about 7 hours (range 2-15 hours). Healthy subjects, patients with stable <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, and patients undergoing PCI show similar pharmacokinetics.</p>
<p><span class="Italics">Absorption and Binding</span> - Following oral administration, â‰¥ 79% of the dose is absorbed. The absorption and metabolism are rapid, with peak plasma concentrationsÂ (C<span class="Sub">max</span>) of the active metabolite occurring approximately 30Â minutes after dosing. The active metabolite's exposureÂ (AUC) increases slightly more than proportionally over the dose range of 5 to 60 mg. Repeated daily doses of 10 mg do not lead to accumulation of the active metabolite. In a study of healthy subjects given a single 15 mg dose, the AUC of the active metabolite was unaffected by a high fat, high calorie meal, but C<span class="Sub">max</span> was decreased by 49% and T<span class="Sub">max</span> was increased from 0.5 to 1.5Â hours. Effient can be administered without regard to food. The active metabolite is bound about 98% to human serum albumin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Metabolism and Elimination</span> - Prasugrel is not detected in plasma following oral administration. It is rapidly hydrolyzed in the intestine to a thiolactone, which is then converted to the active metabolite by a single step, primarily by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. The estimates of apparent volume of distribution of prasugrel's active metabolite ranged from 44 to 68 L and the estimates of apparent clearance ranged from 112 to 166 L/hr in healthy subjects and patients with stable <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. The active metabolite is metabolized to two inactive compounds by S-methylation or conjugation with cysteine. The major inactive metabolites are highly bound to human plasma proteins. Approximately 68% of the prasugrel dose is excreted in the urine and 27% in the feces as inactive metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Pediatric</span> - Pharmacokinetics and pharmacodynamics of prasugrel have not been evaluated in a pediatric population <span class="Italics">[see Use in Specific PopulationsÂ (<a href="#s32">8.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Geriatric</span> - In a study of 32Â healthy subjects between the ages of 20 and 80Â years, age had no significant effect on pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation. In TRITON-TIMI 38, the mean exposureÂ (AUC) of the active metabolite was 19%Â higher in patients â‰¥75Â years of age than in patients &lt;75Â years of age <span class="Italics">[see Warnings and PrecautionsÂ (<a href="#s11">5.1</a>), Adverse ReactionsÂ (<a href="#s16">6.1</a>), and Use in Specific PopulationsÂ (<a href="#s33">8.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Body Weight</span> - The mean exposureÂ (AUC) to the active metabolite is approximately 30 to 40% higher in subjects with a body weight of &lt;60Â kg than in those weighing â‰¥60Â kg <span class="Italics">[see Dosage and AdministrationÂ (<a href="#s4">2</a>), Warnings and PrecautionsÂ (<a href="#s11">5.1</a>), Adverse ReactionsÂ (<a href="#s16">6.1</a>), and Use in Specific PopulationsÂ (<a href="#s34">8.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Italics">Gender</span> - Pharmacokinetics of prasugrel's active metabolite are similar in men and women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Italics">Ethnicity</span> - Exposure in subjects of African and Hispanic descent is similar to that in Caucasians. In clinical pharmacology studies, after adjusting for body weight, the AUC of the active metabolite was approximately 19%Â higher in Chinese, Japanese, and Korean subjects than in Caucasian subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Italics">Smoking</span> - Pharmacokinetics of prasugrel's active metabolite are similar in smokers and <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> - Pharmacokinetics of prasugrel's active metabolite and its inhibition of platelet aggregation are similar in patients with moderate renal impairmentÂ (CrCL=30 to 50Â mL/min) and healthy subjects. In patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, exposure to the active metabolite (both C<span class="Sub">max</span> and AUC(0-t<span class="Sub">last</span>)) was about half that in healthy controls and patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific PopulationsÂ (<a href="#s35">8.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span> - Pharmacokinetics of prasugrel's active metabolite and inhibition of platelet aggregation were similar in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to healthy subjects. The pharmacokinetics and pharmacodynamics of prasugrel's active metabolite in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> have not been studied <span class="Italics">[see Warnings and PrecautionsÂ (<a href="#s11">5.1</a>) and Use in Specific PopulationsÂ (<a href="#s36">8.8</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-11.3.12"></a><p></p>
<p class="First"><span class="Italics">Potential for Other Drugs to Affect Prasugrel</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-11.3.13"></a><p></p>
<p class="First"><span class="Italics">Inhibitors of CYP3A</span> - KetoconazoleÂ (400Â mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect prasugrel-mediated inhibition of platelet aggregation or the active metabolite's AUC and T<span class="Sub">max</span>, but decreased the C<span class="Sub">max</span> by 34% to 46%. Therefore, CYP3A inhibitors such as verapamil, diltiazem, indinavir, ciprofloxacin, clarithromycin, and grapefruit juice are not expected to have a significant effect on the pharmacokinetics of the active metabolite of prasugrel <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-11.3.14"></a><p></p>
<p class="First"><span class="Italics">Inducers of CytochromesÂ P450</span> - RifampicinÂ (600Â mg daily), a potent inducer of CYP3A and CYP2B6 and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation. Therefore, known CYP3A inducers such as rifampicin, carbamazepine, and other inducers of cytochromesÂ P450 are not expected to have significant effect on the pharmacokinetics of the active metabolite of prasugrel <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-11.3.15"></a><p></p>
<p class="First"><span class="Italics">Drugs that Elevate Gastric pH</span> - Daily coadministration of ranitidineÂ (an H<span class="Sub">2</span> blocker) or lansoprazoleÂ (a proton pump inhibitor) decreased the C<span class="Sub">max</span> of the prasugrel active metabolite by 14% and 29%, respectively, but did not change the active metabolite's AUC and T<span class="Sub">max</span>. In TRITON-TIMI 38, Effient was administered without regard to coadministration of a proton pump inhibitor or H<span class="Sub">2</span> blocker <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-11.3.16"></a><p></p>
<p class="First"><span class="Italics">Statins</span> - AtorvastatinÂ (80Â mg daily), a drug metabolized by CYP450 3A4, did not alter the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-11.3.17"></a><p></p>
<p class="First"><span class="Italics">Heparin</span> - A single intravenous dose of unfractionated heparinÂ (100Â U/kg) did not significantly alter coagulation or the prasugrel-mediated inhibition of platelet aggregation; however, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> was increased compared with either drug alone <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-11.3.18"></a><p></p>
<p class="First"><span class="Italics">Aspirin</span> - AspirinÂ 150Â mg daily did not alter prasugrel-mediated inhibition of platelet aggregation; however, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> was increased compared with either drug alone <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-11.3.19"></a><p></p>
<p class="First"><span class="Italics">Warfarin</span> - A significant prolongation of the <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> was observed when prasugrel was coadministered with 15 mg of warfarin <span class="Italics">[see Drug Interactions (<a href="#s25">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-11.3.20"></a><p></p>
<p class="First"><span class="Italics">Potential for Prasugrel to Affect Other Drugs</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-11.3.21"></a><p></p>
<p class="First"><span class="Italics">In vitro</span> metabolism studies demonstrate that prasugrel's main circulating metabolites are not likely to cause clinically significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A, or induction of CYP1A2 or CYP3A.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-11.3.22"></a><p></p>
<p class="First"><span class="Italics">Drugs Metabolized by CYP2B6</span> â€” Prasugrel is a weak inhibitor of CYP2B6. In healthy subjects, prasugrel decreased exposure to hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%, an amount not considered clinically significant. Prasugrel is not anticipated to have significant effect on the pharmacokinetics of drugs that are primarily metabolized by CYP2B6, such as halothane, cyclophosphamide, propofol, and nevirapine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-11.3.23"></a><p></p>
<p class="First"><span class="Italics">Effect on Digoxin</span> - The potential role of prasugrel as a Pgp substrate was not evaluated. Prasugrel is not an inhibitor of Pgp, as digoxin clearance was not affected by prasugrel coadministration <span class="Italics">[see Drug InteractionsÂ (<a href="#s27">7.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-11.4"></a><p></p>
<h2>12.5 Pharmacogenomics</h2>
<p class="First">There is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel's active metabolite or its inhibition of platelet aggregation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s70"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s71"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span> - No compound-related tumors were observed in a 2-year rat study with prasugrel at oral doses up to 100 mg/kg/day (&gt;100 times the recommended therapeutic exposures in humans (based on plasma exposures to the major circulating human metabolite). There was an increased incidence of tumors (<span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span>) in mice exposed for 2Â years to high doses (&gt;250 times the human metabolite exposure).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span> - Prasugrel was not genotoxic in two <span class="Italics">in vitro</span> testsÂ (Ames bacterial gene mutation test, clastogenicity assay in Chinese hamster fibroblasts) and in one <span class="Italics">in vivo</span> testÂ (micronucleus test by intraperitoneal route in mice).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span> - Prasugrel had no effect on fertility of male and female rats at oral doses up to 300 mg/kg/day (80 times the human major metabolite exposure at daily dose of 10 mg prasugrel).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s75"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The clinical evidence for the effectiveness of Effient is derived from the TRITON-TIMI 38Â (<span class="Underline">TR</span>ial to Assess <span class="Underline">I</span>mprovement in <span class="Underline">T</span>herapeutic Outcomes by <span class="Underline">O</span>ptimizing Platelet Inhibitio<span class="Underline">N</span> with Prasugrel) study, a 13,608-patient, multicenter, international, randomized, double-blind, parallel-group study comparing Effient to a regimen of clopidogrel, each added to aspirin and other standard therapy, in patients with ACS (UA, NSTEMI, or <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) who were to be managed with PCI. Randomization was stratified for UA/NSTEMI and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>.</p>
<p>Patients with UA/NSTEMI presenting within 72Â hours of symptom onset were to be randomized after undergoing coronary angiography. Patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> presenting within 12Â hours of symptom onset could be randomized prior to coronary angiography. Patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> presenting between 12Â hours and 14 days of symptom onset were to be randomized after undergoing coronary angiography. Patients underwent PCI, and for both UA/NSTEMI and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> patients, the loading dose was to be administered anytime between randomization and 1Â hour after the patient left the catheterization lab. If patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> were treated with thrombolytic therapy, randomization could not occur until at least 24Â hours (for tenecteplase, reteplase or alteplase) or 48Â hours (for streptokinase) after the thrombolytic was given.</p>
<p>Patients were randomized to receive EffientÂ (60 mg loading dose followed by 10Â mg once daily) or clopidogrelÂ (300 mg loading dose followed by 75Â mg once daily), with administration and follow-up for a minimum of 6Â months (actual median 14.5Â months). Patients also received aspirinÂ (75Â mg to 325Â mg once daily). Other therapies, such as heparin and intravenous glycoproteinÂ IIb/IIIa (GPIIb/IIIa) inhibitors, were administered at the discretion of the treating physician. Oral anticoagulants, other platelet inhibitors, and chronic NSAIDs were not allowed.</p>
<p>The primary outcome measure was the composite of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatalÂ MI, or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in the UA/NSTEMI population. Success in this group allowed analysis of the same endpoint in the overall ACS and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> populations. Nonfatal MIs included both MIs detected solely through analysis of creatine kinase muscle-brain (CK-MB) changes and clinically apparent (investigator-reported) MIs.</p>
<p>The patient population was 92% Caucasian, 26%Â female, and 39% â‰¥65Â years of age. The median time from symptom onset to study drug administration was 7 hours for patients with <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> and 30 hours for patients with UA/NSTEMI. Approximately 99% of patients underwent PCI. The study drug was administered after the first coronary guidewire was placed in approximately 75% of patients.</p>
<p>Effient significantly reduced total endpoint events compared to clopidogrel (<span class="Italics">see </span><a href="#t302">TableÂ 5</a> and <a href="#f04">Figure 3</a>). The reduction of total endpoint events was driven primarily by a decrease in nonfatal MIs, both those occurring early (through 3 days) and later (after 3 days). Approximately 40% of MIs occurred peri-procedurally and were detected solely by changes in CK-MB. Administration of the clopidogrel loading dose in TRITON-TIMI 38 was delayed relative to the placebo-controlled trials that supported its approval for ACS. Effient produced higher rates of clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> than clopidogrel in TRITON-TIMI 38 <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span>. Choice of therapy requires balancing these differences in outcome.</p>
<p>The treatment effect of Effient was apparent within the first few days, and persisted to the end of the study (<a href="#f04">Figure 3</a>). The inset shows results over the first 7 days.</p>
<div class="Figure">
<a name="f03"></a><img alt="
						Figure 3
					" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-09.jpg">
</div>
<div class="Figure">
<a name="f04"></a><img alt="
							Figure 3
						" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-10.jpg"><p class="MultiMediaCaption">Figure 3: Time to first event of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (TRITON-TIMI 38)</p>
</div>
<p>The Kaplan-Meier curves (<a href="#f04">Figure 3</a>) show the primary composite endpoint of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatal MI, or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> over time in the UA/NSTEMI and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> populations. In both populations, the curves separate within the first few hours. In the UA/NSTEMI population, the curves continue to diverge throughout the 15Â month follow-up period. In the <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> population, the early separation was maintained throughout the 15 month follow-up period, but there was no progressive divergence after the first few weeks.</p>
<p>Effient reduced the occurrence of the primary composite endpoint compared to clopidogrel in both the UA/NSTEMI and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> populations (<span class="Italics">see </span><a href="#t302">TableÂ 5</a>). In patients who survived an on-study <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the incidence of subsequent events was also lower in the Effient group.</p>
<a name="t302"></a><table width="100%">
<caption><span>TableÂ 5: Patients with Outcome Events (CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>) in TRITON-TIMI 38</span></caption>
<col align="left" width="35.780%">
<col align="left" width="15.020%">
<col align="left" width="13.400%">
<col align="left" width="27.220%">
<col align="left" width="8.580%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Patients with events</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">From Kaplan-Meier analysis</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Effient</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Clopidogrel</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Relative Risk Reduction (%)</span><span class="Sup">a</span><br><span class="Bold">(95% CI)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> RRR = (1-Hazard Ratio) x 100%. Values with a negative relative risk reduction indicate a relative risk increase.</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">UA/NSTEMI</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N=5044</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N=5030</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatal MI, or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									9.3
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									11.2
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									18.0 (7.3, 27.4)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.002
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									1.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									1.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									2.1 (-30.9, 26.8)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.885
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â Nonfatal MI
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									7.1
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									9.2
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									23.9 (12.7, 33.7)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									&lt;0.001
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â Nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									2.1 (-51.3, 36.7)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.922
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N=1769</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N=1765</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, nonfatal MI, or nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									9.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									12.2
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									20.7 (3.2, 35.1)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.019
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									2.4
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									3.3
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									26.2 (-9.4, 50.3)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.129
								</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â Nonfatal MI
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									6.7
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									8.8
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									25.4 (5.2, 41.2)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.016
								</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
									Â Â Â Â  Â Â Â Â Nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									1.2
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									1.1
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									-9.7 (-104.0, 41.0)
								</td>
<td class="Botrule Rrule" align="center" valign="top">
									0.77
								</td>
</tr>
</tbody>
</table>
<p>The effect of Effient in various subgroups is shown in <a href="#f05">Figures 4</a> andÂ <a href="#f06">5</a>. Results are generally consistent across pre-specified subgroups, with the exception of patients with a history of TIA or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see Contraindications (<a href="#s9">4.2</a>)]</span>. The treatment effect was driven primarily by a reduction in nonfatal MI. The effect in patients â‰¥75 years of age was also somewhat smaller, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk is higher in these individuals <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span>. See below for analyses of patients â‰¥75 years of age with risk factors.</p>
<div class="Figure">
<a name="f05"></a><img alt="
								Figure 4
							" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-11.jpg"><p class="MultiMediaCaption">Figure 4: Subgroup analyses for time to first event of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (HR and 95% CI; TRITON-TIMI 38) â€“ UA/NSTEMI Patients.</p>
</div>
<div class="Figure">
<a name="f06"></a><img alt="
									Figure 5
								" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=effient-tablets-12.jpg"><p class="MultiMediaCaption">Figure 5: Subgroup analyses for time to first event of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (HR and 95% CI; TRITON-TIMI 38) â€“ <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> Patients.</p>
</div>
<p>Effient is generally not recommended in patients â‰¥75 years of age, except in high-risk situations (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or prior MI) where its effect appears to be greater and its use may be considered. These recommendations are based on subgroup analyses (<a href="#t6">Table 6</a>) and must be interpreted with caution, but the data suggest that Effient reduces ischemic events in such patients.</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Subgroup Analyses for Time to First Event of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>: Patients &lt; or â‰¥75 Years of Age, Â± <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>, Â± Prior History of MI, All ACS Patient Population</span></caption>
<col align="left" width="30.567%">
<col align="left" width="10.427%">
<col align="left" width="10.484%">
<col align="left" width="10.427%">
<col align="left" width="10.484%">
<col align="left" width="19.640%">
<col align="left" width="7.970%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Effient</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Clopidogrel</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">% with events</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">% with events</span></th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Hazard Ratio</span><br><span class="Bold">(95% CI)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age â‰¥75</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> - yes
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								249
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								14.9
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								234
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								21.8
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.64 (0.42, 0.97)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.034
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> - no
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								652
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								16.4
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								674
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								15.3
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								1.1 (0.83, 1.43)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								NS
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age &lt;75</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> - yes
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								1327
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								10.8
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								1336
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								14.8
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.72 (0.58, 0.89)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.002
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> - no
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								4585
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								7.8
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								4551
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								9.5
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.82 (0.71, 0.94)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.004
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â 
							</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age â‰¥75</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â Prior MI - yes
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								220
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								17.3
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								212
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								22.6
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.72 (0.47, 1.09)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.12
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â Prior MI - no
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								681
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								15.6
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								696
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								15.2
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								1.05 (0.80, 1.37)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								NS
							</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age &lt;75</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â Prior MI - yes
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								1006
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								12.2
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								996
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								15.4
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.78 (0.62, 0.99)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.04
							</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
								Â Â Â Â Prior MI - no
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								4906
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								7.7
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								4891
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								9.7
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								0.78 (0.68, 0.90)
							</td>
<td class="Botrule Rrule" align="center" valign="top">
								&lt;0.001
							</td>
</tr>
</tbody>
</table>
<p>There were 50% fewer stent thromboses (95% C.I. 32% - 64%; p&lt; 0.001) reported among patients randomized to Effient (0.9%) than among patients randomized to clopidogrel (1.8%). The difference manifested early and was maintained through one year of follow-up. Findings were similar with bare metal and drug-eluting stents.</p>
<p>In TRITON-TIMI 38, prasugrel reduced ischemic events (mainly nonfatal MIs) and increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span> relative to clopidogrel. The findings are consistent with the intended greater inhibition of platelet aggregation by prasugrel at the doses used in the study <span class="Italics">[see Clinical Pharmacology (<a href="#s44">12.2</a>)]</span>. There is, however, an alternative explanation: both prasugrel and clopidogrel are pro-drugs that must be metabolized to their active moieties. Whereas the pharmacokinetics of prasugrel's active metabolite are not known to be affected by genetic variations in CYP2B6, CYP2C9, CYP2C19, or CYP3A5, the pharmacokinetics of clopidogrel's active metabolite are affected by CYP2C19 genotype, and approximately 30% of Caucasians are reduced-metabolizers. Moreover, certain proton pump inhibitors, widely used in the ACS patient population and used in TRITON-TIMI 38, inhibit CYP2C19, thereby decreasing formation of clopidogrel's active metabolite. Thus, reduced metabolizer status and use of proton pump inhibitors may diminish clopidogrel's activity in a fraction of the population, and may have contributed to prasugrel's greater treatment effect and greater <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate in TRITON-TIMI 38. The extent to which these factors were operational, however, is unknown.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s76"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>EffientÂ (prasugrel) 10 mg is supplied as a beige, elongated hexagonal, film-coated, non-scored tablet debossed with â€œ10Â MGâ€? on one side and â€œ4759â€? on the other side.<a name="ief4d21cf-fb7c-45c7-83f1-825b6bdde75f"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-6238-0<br>
</td>
</tr></tbody></table>
<br><p class="First">Store at 25Â°CÂ (77Â°F); excursions permitted to 15Â° to 30Â°CÂ (59Â° to 86Â°F).</p>
<p>Dispense and keep product in original container. Keep container closed and do not remove desiccant from bottle. Do not break the tablet.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s77"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#s83">Medication Guide</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Benefits and Risks</h2>
<ul class="Disc">
<li>
							Summarize the effectiveness features and potential side effects of Effient.
						</li>
<li>
							Tell patients to take Effient exactly as prescribed.
						</li>
<li>
							Remind patients not to discontinue Effient without first discussing it with the physician who prescribed Effient.
						</li>
<li>
							Recommend that patients read the <a href="#s83">Medication Guide</a>.
						</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Inform patients that they:</p>
<ul class="Disc">
<li>
							will <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and bleed more easily.
						</li>
<li>
							will take longer than usual to stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
						</li>
<li>
							should report any unanticipated, prolonged, or excessive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or blood in their stool or urine.
						</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Other Signs and Symptoms Requiring Medical Attention</h2>
<ul class="Disc">
<li>
							Inform patients that TTP is a rare but serious condition that has been reported with Effient.
						</li>
<li>
							Instruct patients to get prompt medical attention if they experience any of the following symptoms that cannot otherwise be explained: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, extreme skin paleness, purple skin patches, yellowing of the skin or eyes, or neurological changes.
						</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Invasive Procedures</h2>
<p class="First">Instruct patients to:</p>
<ul class="Disc">
<li>
							inform physicians and dentists that they are taking Effient before any invasive procedure is scheduled.
						</li>
<li>
							tell the doctor performing the invasive procedure to talk to the prescribing health care professional before stopping Effient.
						</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Concomitant Medications</h2>
<p class="First">Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take so the physician knows about other treatments that may affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk (<span class="Italics">e.g.</span>, warfarin and NSAIDs).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="x99"></a><a name="section-16"></a><p></p>
<p class="First">Literature Revised: December 6, 2010</p>
<p><span class="Bold">Manufactured by Eli Lilly and Company, Indianapolis, IN, 46285</span></p>
<p><span class="Bold">Marketed by Daiichi Sankyo, Inc. and Eli Lilly and Company</span></p>
<p>Copyright Â©2009, 2010, Daiichi Sankyo, Inc. and Eli Lilly and Company. All rights reserved.</p>
<p>PV 7311 AMP</p>
<br><p>Relabeling of<span class="Bold"> "Additional barcode label" </span>by:<br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s83"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">Effientâ„¢Â (Efâ€²-fee-ent)</span></p>
<p><span class="Bold">(prasugrel)</span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read this Medication Guide before you start taking Effient and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about Effient?</span></p>
<ul class="Disc">
<li>
					Effient is used to lower your chance of having a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or other serious problems with your heart or blood vessels. But, Effient can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which can be serious, and sometimes lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. You should not start to take Effient if it is likely that you will have heart bypass surgery (coronary artery bypass graft surgery or CABG) right away. You have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if you take Effient and then have heart bypass surgery.
				</li>
<li>
<span class="Bold">Do not take Effient if you:</span><ul class="Disc">
<li>
					currently have abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, such as stomach or intestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your head
				</li>
<li>
					have a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or â€œmini-strokeâ€? (transient ischemic attack or TIA)
				</li>
<li>
					are allergic to prasugrel or any of the ingredients in Effient.  See the end of this <a href="#s83">Medication Guide</a> for a list of ingredients in Effient.
				</li>
</ul>
</li>
<li>
			You should stop taking Effient if you have a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.
		</li>
<li><span class="Bold">Whenever possible, you should stop taking Effient at least 7 days before any surgery, as instructed by the doctor who prescribed Effient for you.</span></li>
</ul>
<p><span class="Bold">You may also have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if you take Effient and:</span></p>
<ul class="Disc">
<li>
			have had <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, such as an <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> or surgery
		</li>
<li>
			have stomach or intestine <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is recent or keeps coming back, or you have a <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>
		</li>
<li>
			have severe liver problems
		</li>
<li>
			weigh less than 132 pounds
		</li>
<li>
			take other medicines that increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including:
			<ul class="Disc">
<li>
					warfarin sodium (Coumadin*, Jantoven*)
				</li>
<li>
					a medicine that contains heparin
				</li>
<li>
					other medicines to prevent or treat blood clots
				</li>
<li>
					non-steroidal anti-inflammatory drugs (NSAIDs) for a long time
				</li>
</ul>
</li>
</ul>
<p><span class="Bold">Tell your doctor if you take any of these medicines. Ask your doctor if you are not sure if your medicine is one listed above.</span></p>
<ul class="Disc">
<li>
			Effient increases your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> because it lessens the ability of your blood to clot. While you take Effient:
			<ul class="Disc">
<li>
					you will <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and bleed more easily
				</li>
<li>
					you are more likely to have <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleeds</span>
				</li>
<li>
					it will take longer for any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop
				</li>
</ul>
</li>
<li>
			Call your doctor right away if you have any of these signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:
			<ul class="Disc">
<li>
					unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time
				</li>
<li>
					<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is severe or you can not control
				</li>
<li>
					pink or brown urine
				</li>
<li>
					red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar)
				</li>
<li>
					<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> that happen without a known cause or get larger
				</li>
<li>
					<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots
				</li>
<li>
					vomit blood or your vomit looks like â€œcoffee groundsâ€?
				</li>
</ul>
</li>
<li><span class="Bold">
			Do not stop taking Effient without talking to the doctor who prescribes it for you. People who are treated with angioplasty and have a stent, and stop taking Effient too soon, have a higher risk of a blood clot in the stent, having a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or dying. If you must stop Effient because of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, your risk of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> may be higher. See â€œ<a href="#p2">What are the possible side effects of Effient?</a>â€? for more information about side effects.</span></li>
</ul>
<p><span class="Bold">What is Effient?</span></p>
<p>Effient is a prescription medicine used to treat people who:</p>
<ul class="Disc">
<li>
			have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or severe <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that happens when your heart does not get enough oxygen, and
		</li>
<li>
			have been treated with a procedure called â€œangioplastyâ€? (also called balloon angioplasty).
		</li>
</ul>
<p>Effient is used to lower your chance of having another serious problem with your heart or blood vessels, such as another <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, blood clots in your stent, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Platelets are blood cells that help with normal blood clotting. Effient helps prevent platelets from sticking together and forming a clot that can block an artery or a stent.</p>
<p>It is not known if Effient is safe and works in children.</p>
<p><span class="Bold">What should I tell my doctor before taking Effient?</span></p>
<p>Effient may not be right for you. Tell your doctor about all of your medical conditions, including if you:</p>
<ul class="Disc">
<li>
			have any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems
		</li>
<li>
			have a history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span>, colon <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span>, <span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulosis</span>
		</li>
<li>
			have liver problems
		</li>
<li>
			have had any recent severe injury or surgery
		</li>
<li>
			plan to have surgery or a dental procedure. See â€œ<a href="#p1">What is the most important information I should know about Effient?</a>â€?
		</li>
<li>
			pregnant, or are planning to get pregnant. It is not known if Effient will harm your baby.
		</li>
<li>
			if you are breast-feeding. It is not known if Effient passes into your breast-milk. You and your doctor should decide if you will take Effient or breast-feed. You should not do both without talking with your doctor.
		</li>
</ul>
<p>Tell all of your doctors and dentists that you are taking Effient. They should talk to the doctor who prescribed Effient for you, before you have <span class="Bold">any</span> surgery or invasive procedure.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Certain medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. See â€œ<a href="#p1">What is the most important information I should know about Effient?</a>â€?</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Effient?</span></p>
<ul class="Disc">
<li>
			Take Effient exactly as prescribed by your doctor.
		</li>
<li>
			Take Effient one time each day.
		</li>
<li>
			You can take Effient with or without food.
		</li>
<li>
			Take Effient with aspirin as instructed by your doctor.
		</li>
<li>
			Your doctor will decide how long you should take Effient. Do not stop taking Effient without first talking to the doctor who prescribed it for you. See â€œ<a href="#p1">What is the most important information I should know about Effient?</a>â€?
		</li>
<li>
			If you miss a dose, take Effient as soon as you remember. If it is almost time for your next dose, skip the missed dose. Just take the next dose at your regular time. Do not take two doses at the same time unless your doctor tells you to.
		</li>
<li>
			If you take too much Effient, call your local emergency room or poison control center right away.
		</li>
</ul>
<p><span class="Bold">What are the possible side effects of Effient?</span></p>
<p>Effient can cause serious side effects, including:</p>
<ul class="Disc">
<li><span class="Bold">See â€œ<a href="#p1">What is the most important information I should know about Effient?</a>â€?</span></li>
<li>
<span class="Bold">A blood clotting problem called <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic Thrombocytopenic Purpura</span> (TTP).</span> TTP can happen with Effient, sometimes after a short time (less than 2 weeks). TTP is a blood clotting problem where blood clots form in blood vessels and can happen all over the body. TTP needs to be treated in a hospital right away, because you may die. Get medical help right away if you have any of these symptoms and they can not be explained by another medical condition:
	</li>
<li>
		purplish spots called <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> on the skin or mucous membranes (such as on the mouth) due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> under the skin
	</li>
<li>
		paleness or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (a yellowish color of the skin or eyes)
	</li>
<li>
		feeling tired or weak
	</li>
<li>
		<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
	</li>
<li>
		fast heart rate or feeling <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>
	</li>
<li>
		<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, speech changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>
	</li>
<li>
		low amount of urine, or urine that is pink-tinged or has blood in it
	</li>
<li>
		stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
	</li>
<li>
		visual changes
	</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of Effient. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects.</p>
<p>You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Effient?</span></p>
<ul class="Disc">
<li>
		Keep Effient at room temperature between 59Â°F to 86Â°FÂ (15Â°C to 30Â°C).
	</li>
<li>
		Keep Effient in the container it comes in.
	</li>
<li>
		Keep the container closed tightly with the gray cylinder inside.
	</li>
<li>
		Protect Effient from moisture.
	</li>
</ul>
<p>Keep Effient and all medicines out of the reach of children.</p>
<p><span class="Bold">General Information about Effient</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Effient for a condition for which it was not prescribed. Do not give your Effient to other people, even if they have similar symptoms. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Effient. If you would like more information about Effient, talk with your doctor or pharmacist. For more information, call 1-800-545-5979 or go to the following website: www.Effient.com</p>
<p><span class="Bold">What are the ingredients in Effient?</span></p>
<p>Active Ingredient: prasugrel</p>
<p>Inactive Ingredients: mannitol, hypromellose, croscarmellose sodium, microcrystalline cellulose, and vegetable magnesium stearate. The color coatings contain lactose, hypromellose, titanium dioxide, triacetin, iron oxide yellow, and iron oxide red (only in Effient 10 mg tablet).</p>
<p>*The brands listed are trademarks of their respective owners and are not trademarks of Daiichi Sankyo, Inc. or Eli Lilly and Company.</p>
<p>Revised: December 6, 2010</p>
<p><span class="Bold">Manufactured by Eli Lilly and Company, Indianapolis, IN, 46285</span></p>
<p><span class="Bold">Marketed by Daiichi Sankyo, Inc. and Eli Lilly and Company</span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Copyright Â© 2009, 2010, Daiichi Sankyo, Inc. and Eli Lilly and Company. All rights reserved.</p>
<p>PV 6181 AMP</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s86"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ Effient 10 mg 30 Tablets</span></p>
<p><br></p>
<p>Effient <span class="Sub">TM</span></p>
<p>(prasugrel) tablets</p>
<p>10 mg</p>
<p>Rx only</p>
<p>Each tablet contains prasugrel hydrochloride* equivalent to 10 mg prasugrel</p>
<p>*see package insert section 11</p>
<p>Dispense accompanying Medication Guide to each patient.</p>
<div class="Figure"><img alt="image of 10 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb684ad9-0b72-406f-8a07-a419254ccd36&amp;name=6238.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EFFIENTÂ 		
					</strong><br><span class="contentTableReg">prasugrel hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6238(NDC:0002-4759)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRASUGREL HYDROCHLORIDE</strong> (PRASUGREL) </td>
<td class="formItem">PRASUGREL</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">HEXAGON (6 sided) (double-arrow) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10;mg;4759</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6238-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022307</td>
<td class="formItem">03/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>315dd1fe-0930-43f1-b574-a5f5e7f6f7a3</div>
<div>Set id: cb684ad9-0b72-406f-8a07-a419254ccd36</div>
<div>Version: 1</div>
<div>Effective Time: 20110114</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
